Performance study of the automated immunoassay test anti-hepatitis C virus VIDAS® for the qualitative detection of antibodies anti-hepatitis C virus
AbstractBackground and aims: Hepatitis C virus (HCV) represents a major worldwide public health problem requiring global action for the diagnosis, treatment and prevention of this infection. HCV is the leading cause of chronic liver disease, including chronic hepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma and it is responsible for about 350,000 deaths yearly. Anti-HCV assays remain the first choice for screening HCV infection in most clinical laboratories. The anti-HCV VIDAS® (bioMérieux, Marcy L’Etoile, France) test has been recently launched and we aimed to evaluate its performance compared with other widely used methods.
Materials and methods: Routine anti-HCV screening of clinical samples was carried out on the ARCHITECT® i2000SR platform (Abbot Laboratories, Abbott Park, IL, USA); out of 8876 samples tested from October 2012 to May 2013, 70 sera with low positive anti-HCV results (1≤S/CO<8) were collected. These samples were tested for the presence of anti-HCV antibodies using anti-HCV VIDAS® and INNO-LIATM HCV score assays (Innogenetics NV, Ghent, Belgium).
Results and conclusions: Positive anti-HCV results were obtained in 61.4% and 41.4% of sera tested with VIDAS® and INNO-LIATM, respectively. Concordance between methods was 63.2% for ARCHITECT® and VIDAS®, 42.6% for ARCHITECT® and INNO-LIATM, and 79.4% for VIDAS® and INNO-LIATM. Anti-HCV VIDAS® demonstrated superior specificity compared to the anti-HCV test ARCHITECT®; therefore, this assay has been introduced in our routine analysis as a second level screening test to select samples to be subjected to confirmatory anti- HCV immunoblot.
- Abstract views: 1943
- PDF: 718
- HTML: 1984
Copyright (c) 2016 Sara Salvetti, Federica Lavinia, Iolanda Montenora
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.